NO119491B - - Google Patents
Download PDFInfo
- Publication number
- NO119491B NO119491B NO159782A NO15978265A NO119491B NO 119491 B NO119491 B NO 119491B NO 159782 A NO159782 A NO 159782A NO 15978265 A NO15978265 A NO 15978265A NO 119491 B NO119491 B NO 119491B
- Authority
- NO
- Norway
- Prior art keywords
- virus
- piglets
- vaccine
- tissue
- culture
- Prior art date
Links
- 241000700605 Viruses Species 0.000 claims description 45
- 229960005486 vaccine Drugs 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 7
- 238000011081 inoculation Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 5
- 208000005577 Gastroenteritis Diseases 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 description 30
- 241000282887 Suidae Species 0.000 description 13
- 241000057000 ECM virus Species 0.000 description 12
- 241000282898 Sus scrofa Species 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000282465 Canis Species 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A61K39/225—Porcine transmissible gastroenteritis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20064—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39839864A | 1964-09-22 | 1964-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO119491B true NO119491B (en, 2012) | 1970-05-25 |
Family
ID=23575249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO159782A NO119491B (en, 2012) | 1964-09-22 | 1965-09-21 |
Country Status (10)
| Country | Link |
|---|---|
| BE (1) | BE669881A (en, 2012) |
| CH (1) | CH466894A (en, 2012) |
| DE (1) | DE1253412B (en, 2012) |
| DK (1) | DK109407C (en, 2012) |
| FR (1) | FR1563628A (en, 2012) |
| GB (1) | GB1058340A (en, 2012) |
| LU (1) | LU49501A1 (en, 2012) |
| NL (1) | NL6512094A (en, 2012) |
| NO (1) | NO119491B (en, 2012) |
| SE (1) | SE358657B (en, 2012) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3519710A (en) * | 1967-08-10 | 1970-07-07 | Edmund P Bass | Direct active modified live virus vaccine immunization against transmissible gastroenteritis in swine piglets at birth |
| US5911999A (en) * | 1987-09-28 | 1999-06-15 | Pfizer, Inc. | Vaccine based on TGEV for protection of dogs against canine coronavirus |
| CA1332919C (en) * | 1987-09-28 | 1994-11-08 | Dale Bordt | Viral vaccine |
| US6074651A (en) * | 1988-09-14 | 2000-06-13 | Pfizer, Inc. | Vaccine based on TGEV for protection of canines against canine coronavirus |
-
1965
- 1965-09-02 DE DED48111A patent/DE1253412B/de active Pending
- 1965-09-02 CH CH1226365A patent/CH466894A/de unknown
- 1965-09-06 SE SE11606/65A patent/SE358657B/xx unknown
- 1965-09-16 NL NL6512094A patent/NL6512094A/xx unknown
- 1965-09-20 LU LU49501A patent/LU49501A1/xx unknown
- 1965-09-21 FR FR1563628D patent/FR1563628A/fr not_active Expired
- 1965-09-21 BE BE669881D patent/BE669881A/xx unknown
- 1965-09-21 NO NO159782A patent/NO119491B/no unknown
- 1965-09-22 DK DK486365AA patent/DK109407C/da active
- 1965-09-22 GB GB40379/65A patent/GB1058340A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR1563628A (en, 2012) | 1969-04-18 |
| SE358657B (en, 2012) | 1973-08-06 |
| NL6512094A (en, 2012) | 1966-03-23 |
| BE669881A (en, 2012) | 1966-03-21 |
| DE1253412B (de) | 1967-11-02 |
| LU49501A1 (en, 2012) | 1966-03-21 |
| CH466894A (de) | 1968-12-31 |
| DK109407C (da) | 1968-04-22 |
| GB1058340A (en) | 1967-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3911108A (en) | Process of producing bovine milk products containing specific antibodies | |
| Powell | Viral respiratory disease of the horse | |
| NO159782B (no) | Anordning ved fjaersystem, foerst og fremst paa kjoeretoeyer. | |
| DK162421B (da) | Hundeparvovirus-vaccine, fremgangsmaade til fremstilling heraf og virusstamme til brug i vaccinen | |
| Rossiter et al. | An epidemiological model of rinderpest. II. Simulations of the behaviour of rinderpest virus in populations | |
| US3479430A (en) | Indirect passive immunization against transmissible gastroenteritis virus in nursing piglets at birth by active immunization of sows prior to farrowing with transmissible gastroenteritis vaccine and method of producing the same | |
| Lawson et al. | The ERA strain of rabies vaccine | |
| US4040904A (en) | Novel rabies virus vaccine and processes | |
| Schipper et al. | Evaluation of inactivated infectious bovine rhinotracheitis vaccines | |
| Paton et al. | Sows infected in pregnancy with porcine respiratory coronavirus show no evidence of protecting their sucking piglets against transmissible gastroenteritis | |
| Cook | Reovirus type 3 infection in laboratory mice | |
| US3519710A (en) | Direct active modified live virus vaccine immunization against transmissible gastroenteritis in swine piglets at birth | |
| NO119491B (en, 2012) | ||
| US3585108A (en) | Transmissible gastroenteritis vaccines and methods of producing the same | |
| US3704203A (en) | Transmissible gastroenteritis vaccines and methods of producing the same | |
| CN113845588B (zh) | 一种抗猪轮状病毒的卵黄抗体的制备方法及其用途 | |
| EP4129309A1 (en) | Method for producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof | |
| JP3043353B2 (ja) | ワクチン | |
| Overman | Antibody response of suckling mice to mumps virus: II. Relation of onset of antibody production to susceptibility to mumps virus infection | |
| US3122477A (en) | Hog cholera vaccine and method of making the same | |
| RU2395297C1 (ru) | Вакцина инактивированная комбинированная против инфекционного ринотрахеита, вирусной диареи и лептоспироза крупного рогатого скота | |
| Chulan et al. | Vaccination against Newcastle disease | |
| Pipana | Virulence and immunogenicity of cultured Theileria annulata schizonts | |
| RU2457859C1 (ru) | Вакцина против вирусной диареи крупного рогатого скота | |
| RU2395299C1 (ru) | Вакцина инактивированная комбинированная против инфекционного ринотрахеита, вирусной диареи, рота-, коронавирусной болезней и лептоспироза крупного рогатого скота |